Promega, JA1072, CD28 Bioassay

Measure Potency and Stability of Biologics Designed to Activate CD28
96- and 384-well plate compatible
Prequalified according to ICH guidelines
No primary cell culture required
Available in convenient thaw-and-use format
Specifications：
TCR/CD3 Effector Cells (IL-2) J129A 1 × 0.8ml
Fetal Bovine Serum J121A 1 × 4ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 1 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 1 × 1 vial
TCR/CD3 Effector Cells (IL-2) J129A 5 × 0.8ml
Fetal Bovine Serum J121A 5 × 4ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo™ Luciferase Assay Buffer G719A 5 × 10ml
Bio-Glo™ Luciferase Assay Substrate G720A 5 × 1 vial
TCR/CD3 Effector Cells (CPM) (IL-2) J127A 2 × 1ml
FcγRIIb aAPC/CHO-K1 (CPM) J325A 2 × 1ml
Control Ab, Anti-CD28 K123A 1 × 1 each
The CD28 Bioassay is a bioluminescent cell-based assay used to measure the potency and stability of ligands or antibodies that activate CD28. CD28 binds to the B7 family members CD80 and CD86 (collectively referred to as B7 for this bioassay) on antigen-presenting cells (APCs). Co-stimulation of T cells by CD28 activation initiates signaling cascades that result in AP-1 and NFκB transcription factor activation and nuclear translocation. These pathways significantly enhance T cell cytokine production—specifically, interleukin-2 (IL-2)—which promotes T cell proliferation, differentiation and survival.
Antibodies that agonize CD28 have the potential to enhance immune responses against cancer and chronic infection. The CD28 Bioassay reflects the mechanism of action (MOA) of biologics designed to activate CD28.